Biallelic mutations in the ATM gene in T-prolymphocytic leukemia - PubMed (original) (raw)
Biallelic mutations in the ATM gene in T-prolymphocytic leukemia
S Stilgenbauer et al. Nat Med. 1997 Oct.
Abstract
Ataxia-telangiectasia (AT) is an autosomal recessive disorder characterized by cerebellar ataxia, oculocutaneous telangiectasia, immune deficiency, genome instability and predisposition to malignancies, particularly T-cell neoplasms. The responsible gene, designated ataxia-telangiectasia mutated (ATM), was recently identified by positional cloning in the chromosomal region 11q22.3-23.1 (ref. 4, 5) ATM is 150 kb in length, consists of 66 exons and encodes a nuclear phosphoprotein of approximately 350 kDa (ref. 4-9). Although ATM is considered to be a tumorigenic factor in several human cancers, it has not yet been found mutated in tumors of non-AT patients. Given the marked predisposition of AT patients to develop neoplasms of the T-cell lineage, we analyzed a series of T-cell leukemias (T-prolymphocytic leukemia, or T-PLL) in non-AT patients in search of genomic changes associated with the development of this disease. Among the recurrent aberrations identified, deletion of the chromosome arm 11q was very frequent. Subsequent molecular cytogenetic analyses allowed us to define a small commonly deleted segment at 11q22.3-23.1 in 15 of 24 T-PLLs studied. Since this critical region contained ATM, we further analyzed the remaining copy of the gene in six cases showing deletions affecting one ATM allele. In all six cases, mutations of the second ATM allele were identified, leading to the absence, premature truncation or alteration of the ATM gene product. Thus, our study demonstrates disruption of both ATM alleles by deletion or point mutation in T-PLL, suggesting that ATM functions as a tumor-suppressor gene in tumors of non-AT individuals.
Similar articles
- Inactivation of the ATM gene in T-cell prolymphocytic leukemias.
Stoppa-Lyonnet D, Soulier J, Laugé A, Dastot H, Garand R, Sigaux F, Stern MH. Stoppa-Lyonnet D, et al. Blood. 1998 May 15;91(10):3920-6. Blood. 1998. PMID: 9573030 - Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.
Vorechovský I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC, Foroni L, Hammarström L, Webster AD, Yuille MA. Vorechovský I, et al. Nat Genet. 1997 Sep;17(1):96-9. doi: 10.1038/ng0997-96. Nat Genet. 1997. PMID: 9288106 - Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL.
Luo L, Lu FM, Hart S, Foroni L, Rabbani H, Hammarström L, Yuille MR, Catovsky D, Webster AD, Vorechovský I. Luo L, et al. Cancer Res. 1998 Jun 1;58(11):2293-7. Cancer Res. 1998. PMID: 9622061 - ATM mutations in sporadic lymphoid tumours.
Stankovic T, Stewart GS, Byrd P, Fegan C, Moss PA, Taylor AM. Stankovic T, et al. Leuk Lymphoma. 2002 Aug;43(8):1563-71. doi: 10.1080/1042819021000002884. Leuk Lymphoma. 2002. PMID: 12400598 Review. - Ataxia telangiectasia gene mutations in leukaemia and lymphoma.
Boultwood J. Boultwood J. J Clin Pathol. 2001 Jul;54(7):512-6. doi: 10.1136/jcp.54.7.512. J Clin Pathol. 2001. PMID: 11429421 Free PMC article. Review.
Cited by
- ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes.
Delia D, Mizutani S, Panigone S, Tagliabue E, Fontanella E, Asada M, Yamada T, Taya Y, Prudente S, Saviozzi S, Frati L, Pierotti MA, Chessa L. Delia D, et al. Br J Cancer. 2000 Jun;82(12):1938-45. doi: 10.1054/bjoc.2000.1168. Br J Cancer. 2000. PMID: 10864201 Free PMC article. - SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
Johansson P, Klein-Hitpass L, Choidas A, Habenberger P, Mahboubi B, Kim B, Bergmann A, Scholtysik R, Brauser M, Lollies A, Siebert R, Zenz T, Dührsen U, Küppers R, Dürig J. Johansson P, et al. Blood Cancer J. 2018 Jan 19;8(1):11. doi: 10.1038/s41408-017-0036-5. Blood Cancer J. 2018. PMID: 29352181 Free PMC article. Clinical Trial. - Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Jain P, et al. Ann Oncol. 2017 Jul 1;28(7):1554-1559. doi: 10.1093/annonc/mdx163. Ann Oncol. 2017. PMID: 28379307 Free PMC article. - Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.
Fang NY, Greiner TC, Weisenburger DD, Chan WC, Vose JM, Smith LM, Armitage JO, Mayer RA, Pike BL, Collins FS, Hacia JG. Fang NY, et al. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5372-7. doi: 10.1073/pnas.0831102100. Epub 2003 Apr 15. Proc Natl Acad Sci U S A. 2003. PMID: 12697903 Free PMC article. - Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Staber PB, et al. Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Blood. 2019. PMID: 31292114 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous